Stephen J Greene, Giorgi Tskhvarashvili, Phuong Tran, Ruben Hermans, Shirin Enshaeifar, Atif Adam, Monica Martinez Traba, Niklas Schmedt, Ayman Alhamdow PMID: 42770322 DOI: 10.1093/eschf/xvag242 Background Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are a foundational therapy for heart failure (HF), yet initiation is frequently delayed in clinical practice. Evidence comparing outcomes associated with early versus delayed or no […]
Sara J Cromer, Helen Tesfaye, Hanseul Cho, Deborah J Wexler, Janinne Ortega-Montiel, Niklas Schmedt, Christina M Shay, Julie M Paik, Elisabetta Patorno PMID: 42765974 DOI: 10.2337/dca26-0039 Objective We aimed to explore the heterogeneity of empagliflozin treatment effects on major adverse cardiovascular events (MACE), hospitalization for heart failure (HHF), and all-cause mortality (ACM) across sociodemographic and […]
Phyo T Htoo, Hanseul Cho, Julie M Paik, Katsiaryna Bykov, Brendan M Everett, Robert J Glynn, Christina Shay, Niklas Schmedt, Deborah J Wexler, Elisabetta Patorno PMID: 42437918 DOI: 10.1186/s12933-026-03287-w Background Evidence on the cardiovascular benefits of combining empagliflozin with glucagon-like peptide-1 receptor agonists (GLP-1RA) is limited, derived primarily from indirect comparisons or subgroup analyses of […]
Stephen J Greene, Atif Adam, Niklas Schmedt, Christian Carlsen, Milou Brand, Eleanor Davies, Laurence Sophie Jouaville Abrouk, Juergen H Prochaska, Phuong Tran, Ayman Alhamdow PMID: 41804888 PMCID: PMC13055654 DOI: 10.1161/JAHA.125.044785 Background Randomized trials and clinical guidelines support early initiation of guideline-directed medical therapy (GDMT) for heart failure (HF). The EMPACE (Treatment Patterns of Guideline-Directed Medical […]
Phyo Than Htoo, Helen Tesfaye, Sebastian Schneeweiss, Deborah J Wexler, Robert J Glynn, Elyse DiCesare, Ariel Freedman, Niklas Schmedt, Christina Shay, Julie M Paik, Elisabetta Patorno PMID: 41090391 DOI: 10.1111/dom.70195 Aims Understanding the real-world impact of treatment with empagliflozin and glucagon-like peptide-1 receptor agonists (GLP-1RA) on healthcare resource utilization (HCRU) and costs could help inform […]
Niklas Schmedt, Ayman Alhamdow, Giorgi Tskhvarashvili, Laura Saarelainen, Xu Qiao, Muriel Lobier, Fabian Hoti PMID: 40511488 PMCID: PMC12232032 DOI: 10.1111/dom.16477 Aims This study aimed to assess the risk of urinary tract cancers (UTCs), including bladder and renal cancers, in people with type 2 diabetes (T2D) initiating empagliflozin compared with people initiating any dipeptidyl peptidase-4 inhibitor […]
Helen Tesfaye, Julie M Paik, Miin Roh, Phyo T Htoo, Heidi Zakoul, Niklas Schmedt, Lisette Koeneman, Deborah J Wexler, Elisabetta Patorno PMID: 39636645 PMCID: PMC11622102 DOI: 10.1001/jamaophthalmol.2024.5219 Importance Empagliflozin might lower the risk of diabetic retinopathy (DR) by preventing retinal pericyte loss. However, the role of empagliflozin with respect to DR in patients with type […]
Phyo Than Htoo, Mehdi NajafZadeh, Helen Tesfaye, Sebastian Schneeweiss, Deborah J Wexler, Robert J Glynn, Niklas Schmedt, Anouk Déruaz-Luyet, Lisette Koeneman, Julie M Paik, Elisabetta Patorno PMID: 38917305 PMCID: PMC11502532 DOI: 10.2337/dc24-0270 Objective We compared health care resource utilization (HCRU) and costs for inpatient and outpatient services and dispensed medications in older adults with type […]
